Standard effect sizes are more meaningful outcomes in Alzheimer's disease drug trials than the widely used metric of percent slowing of decline, an analysis suggested. In recent trials of Alzheimer's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback